Zymeworks Inc. (ZYME)

Market Cap	624.53M
Revenue (ttm)	76.01M
Net Income (ttm)	-118.67M
Shares Out	70.57M
EPS (ttm)	-1.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	536,608
Open	8.65
Previous Close	8.67
Day's Range	8.65 - 8.99
52-Week Range	6.02 - 13.14
Beta	1.11
Analysts	Strong Buy
Price Target	15.25 (+72.32%)
Earnings Date	May 6, 2024

About ZYME

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 28, 2017
• Employees: 272
• Stock Exchange: NASDAQ
• Ticker Symbol: ZYME

Analyst Forecast

According to 4 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price forecast is $15.25, which is an increase of 72.32% from the latest price.

Price Target

$15.25

(72.32% upside)

Analyst Consensus: Strong Buy